openPR Logo
Press release

Enbrel Biosimilars Clinical Trial Insight

06-30-2017 07:26 AM CET | Health & Medicine

Press release from: PNS Pharma

“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on October 23, 2012, but, in the United States, a second patent, granting exclusivity for another 16 years, has been granted.

Etanercept or Enbrel is a biopharmaceutical that has been designed to treat autoimmune diseases by interfering with Tumor necrosis factor. It is a TNF inhibitor which is made in living cell cultures rather than in a chemistry lab. It was one of the first successful products to emerge from the flourishing of innovations in cell biology since the 1990s.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Enbrel-Biosimilars-Clinical-Trial-%26-Opportunity-Insight

Structurally, Enbrel (etanercept) is a dimeric fusion protein consisting of the extracellular ligand binding portion of the human 75 Kilo Dalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human immunoglobulin (IgG1). Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 Kilo Daltons.

Enbrel is usually indicated for treatment of moderately to severely active rheumatoid arthritis (RA) in adults. It is effective in reducing the signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function. It is also used for the improvement of physical function in adult patients with psoriatic arthritis (PsA). Another role of Enbrel is for the management of adult patients with chronic moderate to severe plaque psoriasis.

The mechanism of Enbrel includes the induction of immune response by attracting additional white blood cells to sites of inflammation and through additional molecular mechanisms which initiate and amplify inflammation. Inhibition of its action by etanercept reduces the inflammatory response which is especially useful for treating autoimmune diseases.

TNF receptors are found on the surface of almost all nucleated cells, it imitates the inhibitory effects of naturally occurring soluble TNF receptors, the difference being that etanercept, because it is a fusion protein rather than a simple TNF receptor, has a greatly extended half-life in the bloodstream, and therefore a more profound and long lasting biologic effect than a naturally occurring soluble TNF receptor.

Etanercept was developed by researchers at Immunex, and was released for commercial use in late 1998 after its FDA approval, which was the first chimeric monoclonal antibody against TNF-α to be marketed for clinical use. In North America, etanercept is co-marketed by Amgen and Pfizer under the trade name Enbrel in two separate formulations, one in powder form, and the other as a pre-mixed liquid. Wyeth was the sole marketer of Enbrel outside North America excluding Japan where Takeda Pharmaceuticals markets the drug.

There are some patents of Enbrel at issue include two patents owned by Hoffmann-La Roche Inc. and exclusively licensed to Immunex Corporation (U.S. Patent Nos. 8,063,182 and 8,163,522), and three patents owned by Immunex (U.S. Patent Nos. 7,915,225, 8,119,605, and 8,722,631). Immunex is a wholly owned subsidiary of Amgen Inc., and granted exclusive (sub) licenses to the patents to Amgen Manufacturing Limited, another wholly owned subsidiary of Amgen Inc.

The Indian pharmaceutical major Cipla made an announcement about launching the first biosimilar of Etanercept in India under the brand name 'Etacept' for the treatment of rheumatic disorders in 2013. The company's claimed that the biosimilar will cost 30% less as compared to the innovator. However, Enbrel is costly in U.S. as in 2008; the cost of Enbrel was reported to be US$ 1,500 per month or US$ 18,000 per year.By 2011, the cost had reportedly exceeded US$ 20,000 per year.Enbrel is more expensive in the U.S. than in other countries.

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Enbrel Biosimilars Clinical Trial Insight here

News-ID: 602959 • Views: 203

More Releases from PNS Pharma

Global Cancer Vaccine Market & Clinical Trial Insight 2025
Recent published report “Global Cancer Vaccine Market & Clinical Trial Insight 2025“ by PNS Pharma highlights on going developments in the field of cancer vaccine market research and clinical trials. currently there are more than 15 cancer vaccines commercially available in the market and close to 370 are in clinical Trial or pipeline. Most of the vaccines in development phases are for the treatment of Breast cancer and
Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025” Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Report TOC Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
Global Orphan Drug Pipeline & Regulatory Insight 2025
” Global Orphan Drug Pipeline & Regulatory Insight 2025″ Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025 Orphan Drugs: Regimens For Rare Diseases Drivers of Orphan Drug Commercialization 2.1 Cost
Global Cancer Vaccine Market & Clinical Trial Insight 2025
Global Cancer Vaccine Market & Clinical Trial Insight 2025″ Report Highlight: Global Cancer Vaccine Market Opportunity: US$ 15 Billion Opportunity Personalized Cancer Vaccine: The Next growth Frontier Global Cancer Vaccine Clinical insight by Indication & Phase of Development Global Cancer Vaccine Pipeline: 369 Cancer Vaccines Marketed Cancer Vaccines: 17 Cancer Vaccines Maximum Vaccines in Pipeline for Brain & Breast Cancer: 43 Cancer Vaccines Regulatory Landscape Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Vaccine-Market-%26-Clinical-Trial-Insight-2025 Introduction to Cancer Vaccines Mechanism

All 5 Releases


More Releases for Enbrel

Auto-Injectors Market By Unilife Co., Scandinavian Health Ltd, Kaleo Inc., Amedr …
Global Auto-Injectors Market - Key Players Some of the key players in this market are: UNILIFE CORPORATION Scandinavian Health Ltd Owen Mumford Ltd. (UK) kaleo, Inc. Amedra Pharmaceuticals LLC Enbrel Global Auto-Injectors Market - Insights Auto-Injectors is defined as a medical device which is designed to deliver a single dose of a life-saving drug. Auto injectors are easy to use and are intended for self –administration by patients or can be administered by untrained personnel. These injectors were
Auto-Injectors Market Analysis with Worldwide Key Vendors – Unilife Co., Scand …
Auto-Injectors is defined as a medical device which is designed to deliver a single dose of a particular life-saving drug. Auto injectors are easy to use and are intended for self –administration by patients or can be administered by untrained personnel. These injectors were initially designed to overcome the hesitation associated with self-administration of the needle-based drug delivery device. Most of the injectors are springe-loaded based. Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2046 Currently,
Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pi …
“Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pipeline Outlook 2024” Report Highlights: * Global TNF Inhibitors Market Trends * Key TNF Inhibitors Drug Sales, Price and Dosage Analysis * Global TNF Inhibitors Clinical Pipeline by Company, Indication and Phase * Sales Projections of Key Drugs Till 2024 * Clinical Pipeline Data by Phase * TNF Inhibitors Market Future Outlook * Marketed Drug Clinical and Patent Insight Download Report Sample Weblink: https://www.kuickresearch.com/report-global-tumor-necrosis-factor-inhibitors-drug-market-dosage-price-and-clinical-pipeline-outlook-2024.php For Report Sample
Auto-Injectors Market is expected to reach USD 2.4 billion and CAGR will Grow ~1 …
An auto injector is a type of medical device which is used for injecting oneself with single, preloaded dose of a drug. The medical device typically consists of a spring-loaded syringe activated when the device is pushed firmly against the body. Auto-injectors are commonly used by people with allergies. These allergic reactions can be mild and can become life-threatening reaction. Auto-injectors are used for treatment of anaphylaxis, multiple sclerosis, rheumatoid
Auto-Injectors Market is Expected to Grow with CAGR of 17.2% by 2022- Kaleo, Inc …
Auto injector market is expected to grow with CAGR of 17.2% from 2016 to 2022, Is Expected to Increase by USD 2.9 Billion by the End of 2022 Market Highlights Auto injector is defined as a medical device designed to deliver a single dose of a particular drug, usually life -saving. Most auto injectors are spring-loaded syringes. These injectors were initially designed to overcome unwillingness associated with self-administration of the needle-based drug
Auto-Injectors Market is Expected to Grow with CAGR of 17.2% by 2022- Kaleo, Inc …
Auto injector market is expected to grow with CAGR of 17.2% from 2016 to 2022, Is Expected to Increase by USD 2.9 Billion by the End of 2022 Market Highlights Auto injector is defined as a medical device designed to deliver a single dose of a particular drug, usually life -saving. Most auto injectors are spring-loaded syringes. These injectors were initially designed to overcome unwillingness associated with self-administration of the needle-based drug